Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 3/2001

01-09-2001 | Original Article

Kidney cancer: The cytokine working group experience (1986–2001)

Part II: Management of IL-2 toxicity and studies with other cytokines

Authors: Janice Dutcher, M.D., Michael B. Atkins, Kim Margolin, Geoff Weiss, Joseph Clark, Jeff Sosman, Theodore Logan, Fred Aronson, James Mier, for the Cytokine Working Group

Published in: Medical Oncology | Issue 3/2001

Login to get access
Metadata
Title
Kidney cancer: The cytokine working group experience (1986–2001)
Part II: Management of IL-2 toxicity and studies with other cytokines
Authors
Janice Dutcher, M.D.
Michael B. Atkins
Kim Margolin
Geoff Weiss
Joseph Clark
Jeff Sosman
Theodore Logan
Fred Aronson
James Mier
for the Cytokine Working Group
Publication date
01-09-2001
Publisher
Humana Press
Published in
Medical Oncology / Issue 3/2001
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1385/MO:18:3:209

Other articles of this Issue 3/2001

Medical Oncology 3/2001 Go to the issue

Case Report

Extragonadal seminoma after renal transplantation and immunosuppression; treatment in the presence of renal dysfunction

Original Article

Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures

Letter

Ca 19-9 in the monitoring of colorectal cancer after surgery

Original Article

Identification of a gene frequently mutated in prostate tumors

Original Article

Kidney cancer: The cytokine working group experience (1986–2001)

Case Report

Busulfan-induced loss of Ph chromosome in chronic myeloid leukemia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits